Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss.

Sun L, Vukicevic S, Baliram R, Yang G, Sendak R, McPherson J, Zhu LL, Iqbal J, Latif R, Natrajan A, Arabi A, Yamoah K, Moonga BS, Gabet Y, Davies TF, Bab I, Abe E, Sampath K, Zaidi M.

Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4289-94. doi: 10.1073/pnas.0712395105. Epub 2008 Mar 10.

2.

Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.

Sampath TK, Simic P, Sendak R, Draca N, Bowe AE, O'Brien S, Schiavi SC, McPherson JM, Vukicevic S.

J Bone Miner Res. 2007 Jun;22(6):849-59.

3.

Genetic confirmation for a central role for TNFα in the direct action of thyroid stimulating hormone on the skeleton.

Sun L, Zhu LL, Lu P, Yuen T, Li J, Ma R, Baliram R, Moonga SS, Liu P, Zallone A, New MI, Davies TF, Zaidi M.

Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9891-6. doi: 10.1073/pnas.1308336110. Epub 2013 May 28. Erratum in: Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12498. Baliram, Ramkumari [corrected to Baliram, Ramkumarie].

4.

TNFalpha mediates the skeletal effects of thyroid-stimulating hormone.

Hase H, Ando T, Eldeiry L, Brebene A, Peng Y, Liu L, Amano H, Davies TF, Sun L, Zaidi M, Abe E.

Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12849-54. Epub 2006 Aug 14.

5.

TSH is a negative regulator of skeletal remodeling.

Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M.

Cell. 2003 Oct 17;115(2):151-62.

6.

Thyroid-stimulating hormone, thyroid hormones, and bone loss.

Zaidi M, Davies TF, Zallone A, Blair HC, Iqbal J, Moonga SS, Mechanick J, Sun L.

Curr Osteoporos Rep. 2009 Jul;7(2):47-52.

PMID:
19631028
7.

Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling.

Baliram R, Sun L, Cao J, Li J, Latif R, Huber AK, Yuen T, Blair HC, Zaidi M, Davies TF.

J Clin Invest. 2012 Oct;122(10):3737-41. doi: 10.1172/JCI63948. Epub 2012 Sep 17.

8.

Thyroid-stimulating hormone maintains bone mass and strength by suppressing osteoclast differentiation.

Zhang W, Zhang Y, Liu Y, Wang J, Gao L, Yu C, Yan H, Zhao J, Xu J.

J Biomech. 2014 Apr 11;47(6):1307-14. doi: 10.1016/j.jbiomech.2014.02.015. Epub 2014 Feb 19.

PMID:
24629929
9.

TSH and bone loss.

Sun L, Davies TF, Blair HC, Abe E, Zaidi M.

Ann N Y Acad Sci. 2006 Apr;1068:309-18. Review.

PMID:
16831931
10.
11.

Thyroid hormone independent associations between serum TSH levels and indicators of bone turnover in cured patients with differentiated thyroid carcinoma.

Heemstra KA, van der Deure WM, Peeters RP, Hamdy NA, Stokkel MP, Corssmit EP, Romijn JA, Visser TJ, Smit JW.

Eur J Endocrinol. 2008 Jul;159(1):69-76. doi: 10.1530/EJE-08-0038. Epub 2008 Apr 7.

12.

[Hormones and osteoporosis update. Possible roles of pituitary hormones, TSH and FSH, for bone metabolism].

Takeuchi Y.

Clin Calcium. 2009 Jul;19(7):977-83. doi: CliCa0907977983. Review. Japanese.

PMID:
19567994
13.

The biphenyl-carboxylate derivative ABD328 is a novel orally active antiresorptive agent.

Idris AI, Coste E, Greig IR, Ralston SH, van't Hof RJ.

Calcif Tissue Int. 2010 Dec;87(6):525-32. doi: 10.1007/s00223-010-9417-5. Epub 2010 Sep 18.

PMID:
20852852
14.

Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.

Pierroz DD, Bonnet N, Baldock PA, Ominsky MS, Stolina M, Kostenuik PJ, Ferrari SL.

J Biol Chem. 2010 Sep 3;285(36):28164-73. doi: 10.1074/jbc.M110.101964. Epub 2010 Jun 17.

15.
16.

Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the Rotterdam Study.

van der Deure WM, Uitterlinden AG, Hofman A, Rivadeneira F, Pols HA, Peeters RP, Visser TJ.

Clin Endocrinol (Oxf). 2008 Feb;68(2):175-81. Epub 2007 Sep 4.

PMID:
17803697
17.

Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.

Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, Iorio S, Giustina A, Amato G, Carella C.

J Bone Miner Res. 2005 Mar;20(3):480-6. Epub 2004 Nov 29.

18.
19.

Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation.

Zaiss MM, Sarter K, Hess A, Engelke K, Böhm C, Nimmerjahn F, Voll R, Schett G, David JP.

Arthritis Rheum. 2010 Aug;62(8):2328-38. doi: 10.1002/art.27535.

20.

KMUP-1 suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss: roles of MAPKs, Akt, NF-κB and calcium/calcineurin/NFATc1 pathways.

Liou SF, Hsu JH, Lin IL, Ho ML, Hsu PC, Chen LW, Chen IJ, Yeh JL.

PLoS One. 2013 Jul 25;8(7):e69468. doi: 10.1371/journal.pone.0069468. Print 2013.

Supplemental Content

Support Center